AF implicated in unexpected cardiac death By Caroline Price.

The median follow-up was 13.1 years for both scholarly studies. Crude incidence prices of SCD in the ARIC Research were 2.89 per 1000 person-years among individuals who developed AF, compared with 1.30 per 1000 person-years among those that didn’t; in the CHS, the corresponding rates were 12.00 versus 3.82 per 1000 person-years. Hazard ratios for SCD and non-SCD in meta-analysis of the two studies were 2.47 and 2.98, respectively, after adjusting for age, gender, and race, as well as a raft of risk factors and other potential confounders including body mass index, smoking, diabetes, CHD, left ventricular hypertrophy, and antiarrhythmic drug use.Fischer, M.D., Tuija Vasankari, M.D., K.E. Juhani Airaksinen, M.D., Marcin Fijalkowski, M.D., Andrzej Rynkiewicz, M.D., Maciej Pawlak, M.D., Grzegorz Opolski, M.D., Rafal Dworakowski, M.D., Philip MacCarthy, M.D., Ph.D., Christoph Kaiser, M.D., Stefan Osswald, M.D., Leonarda Galiuto, M.D., Filippo Crea, M.D., Wolfgang Dichtl, M.D., Ph.D., Wolfgang M. Franz, M.D., Klaus Empen, M.D., Stephan B. Felix, M.D.D., Olivier Lairez, M.D., Ph.D., Paul Erne, M.D., Jeroen J. Bax, M.D., Ph.D., Ian Ford, Ph.D., Frank Ruschitzka, M.D., Abhiram Prasad, M.D., and Thomas F.D.: Clinical Features and Outcomes of Takotsubo Cardiomyopathy.. AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection AMAG Pharmaceuticals, Inc. The ongoing company will present further information at the 28th Annual J.P.